Drug Profile
Research programme: respiratory syncytial virus therapeutics - Il-Yang Pharmaceuticals
Alternative Names: RSV therapeutics - Il-Yang PharmaceuticalsLatest Information Update: 25 Jul 2023
Price :
$50
*
At a glance
- Originator Il-Yang
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 25 Jul 2023 Discontinued - Preclinical for Respiratory syncytial virus infections in South Korea (unspecified route)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in South Korea
- 12 May 2014 Preclinical trials in Respiratory syncytial virus infections in South Korea (unspecified route)